Home › Funds › Candriam S.C.A. › ABT

Candriam S.C.A. position in ABT

ABBOTT LABORATORIES · Health Care

Candriam S.C.A. reported holding 1,151,288 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$114.2M, representing 0.51% of its reported portfolio and ranking #39 among its reported holdings. Candriam S.C.A. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.15M sh
Reported value held$114.20M
Portfolio Weight0.51%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Candriam S.C.A.'s ABT position evolved

Candriam S.C.A. first disclosed a stake in ABT in Q3 2023 at 745,532 shares (US$72.2M). The position peaked in Q3 2025 at 1,172,360 shares, worth US$157.0M. Across 13 filings, Candriam S.C.A. increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,151,288 shares valued at US$114.2M — an increase of 940,121 shares quarter over quarter.. Notable position changes include a 81% increase in Q4 2024 (shares rose 18% over the following quarter), a 66% trim in Q2 2026 (shares rose 10% over the following quarter), a 445% increase in Q3 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 745.53K $72.20M New
Q4 2023 626.43K $68.95M Reduce
Q1 2024 303.51K $34.50M Reduce
Q2 2024 359.68K $37.37M Add
Q3 2024 328.00K $37.39M Reduce
Q4 2024 593.75K $67.16M Add
Q1 2025 639.07K $84.77M Add
Q2 2025 1.05M $142.39M Add
Q3 2025 1.17M $157.03M Add
Q4 2025 1.02M $127.65M Reduce
Q1 2026 624.44K $64.11M Reduce
Q2 2026 211.17K $19.14M Reduce
Q3 2026 1.15M $114.20M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Candriam S.C.A. held ABT?

Candriam S.C.A. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Candriam S.C.A.'s current position in ABT?

As of Q3 2026, Candriam S.C.A. holds 1.15M shares of ABT (ABBOTT LABORATORIES), valued at $114.20M, representing 0.51% of its reported portfolio and ranking #39.

Has Candriam S.C.A. been buying or selling ABT?

In the latest 13F filing (Q3 2026), Candriam S.C.A. increased its position in ABT. The position peaked in Q3 2025 at 1.17M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.